146 related articles for article (PubMed ID: 1835624)
21. Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
Tan EH; Ang PT; Khoo KS
Support Care Cancer; 1994 May; 2(3):197-200. PubMed ID: 8032707
[TBL] [Abstract][Full Text] [Related]
22. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
23. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
24. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Support Care Cancer; 1994 May; 2(3):167-70. PubMed ID: 8032702
[TBL] [Abstract][Full Text] [Related]
25. Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis.
Lee CW; Suh CW; Lee JS; Lee KH; Cho GY; Kim SW; Kim SH
J Korean Med Sci; 1994 Oct; 9(5):369-75. PubMed ID: 7702784
[TBL] [Abstract][Full Text] [Related]
26. Improved control of emesis and quality of life with ondansetron in breast cancer.
Clavel M; Soukop M; Greenstreet YL
Oncology; 1993; 50(3):180-5. PubMed ID: 8459989
[TBL] [Abstract][Full Text] [Related]
27. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.
Priestman TJ; Roberts JT; Lucraft H; Collis CH; Adams M; Upadhyaya BK; Priestman S
Clin Oncol (R Coll Radiol); 1990 Mar; 2(2):71-5. PubMed ID: 1702012
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
[TBL] [Abstract][Full Text] [Related]
29. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery.
Desilva PH; Darvish AH; McDonald SM; Cronin MK; Clark K
Anesth Analg; 1995 Jul; 81(1):139-43. PubMed ID: 7598243
[TBL] [Abstract][Full Text] [Related]
31. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
32. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
Beck TM; Ciociola AA; Jones SE; Harvey WH; Tchekmedyian NS; Chang A; Galvin D; Hart NE
Ann Intern Med; 1993 Mar; 118(6):407-13. PubMed ID: 8439113
[TBL] [Abstract][Full Text] [Related]
34. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer.
Soukop M; McQuade B; Hunter E; Stewart A; Kaye S; Cassidy J; Kerr D; Khanna S; Smyth J; Coleman R
Oncology; 1992; 49(4):295-304. PubMed ID: 1387929
[TBL] [Abstract][Full Text] [Related]
35. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Roila F; Basurto C; Minotti V; Ballatori E; Tonato M; Del Favero A
Oncology; 1988; 45(5):346-9. PubMed ID: 3412741
[TBL] [Abstract][Full Text] [Related]
36. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
Sigsgaard T; Herrstedt J; Handberg J; Kjaer M; Dombernowsky P
J Clin Oncol; 2001 Apr; 19(7):2091-7. PubMed ID: 11283143
[TBL] [Abstract][Full Text] [Related]
37. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
J Clin Oncol; 1993 Dec; 11(12):2396-404. PubMed ID: 8246029
[TBL] [Abstract][Full Text] [Related]
38. Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis.
Hesketh PJ
Semin Oncol; 1992 Aug; 19(4 Suppl 10):33-40. PubMed ID: 1387248
[TBL] [Abstract][Full Text] [Related]
39. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients.
Stewart A; McQuade B; Cronje JD; Goedhals L; Gudgeon A; Corette L; Froger X; Tubiana-Hulin M; Laplaige P; Roberts JT
Oncology; 1995; 52(3):202-10. PubMed ID: 7715904
[TBL] [Abstract][Full Text] [Related]
40. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
